These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16968960)

  • 1. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD).
    Tsou VM; Baker R; Book L; Hammo AH; Soffer EF; Wang W; Comer GM;
    Clin Pediatr (Phila); 2006 Oct; 45(8):741-9. PubMed ID: 16968960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease.
    Tolia V; Bishop PR; Tsou VM; Gremse D; Soffer EF; Comer GM;
    J Pediatr Gastroenterol Nutr; 2006 Apr; 42(4):384-91. PubMed ID: 16641576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
    Haag S; Holtmann G
    Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J; van Rensburg C; Vieweg W; Fischer R
    Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.
    Gold BD; Gunasekaran T; Tolia V; Wetzler G; Conter H; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):520-9. PubMed ID: 18030228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial.
    Scholten T; Dekkers CP; Schütze K; Körner T; Bohuschke M; Gatz G
    Digestion; 2005; 72(2-3):76-85. PubMed ID: 16113546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
    Mönnikes H; Pfaffenberger B; Gatz G; Hein J; Bardhan KD
    Digestion; 2005; 71(3):152-8. PubMed ID: 15870503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
    Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease.
    Pai VG; Pai NV; Thacker HP; Shinde JK; Mandora VP; Erram SS
    World J Gastroenterol; 2006 Oct; 12(37):6017-20. PubMed ID: 17009401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.
    Remes-Troche JM; Sobrino-Cossío S; Soto-Pérez JC; Teramoto-Matsubara O; Morales-Arámbula M; Orozco-Gamiz A; Tamayo de la Cuesta JL; Mateos G
    Clin Drug Investig; 2014 Feb; 34(2):83-93. PubMed ID: 24347282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
    Goh KL; Benamouzig R; Sander P; Schwan T;
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):205-11. PubMed ID: 17301646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux.
    Wo JM; Koopman J; Harrell SP; Parker K; Winstead W; Lentsch E
    Am J Gastroenterol; 2006 Sep; 101(9):1972-8; quiz 2169. PubMed ID: 16968502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study.
    Richter JE; Long JF
    Am J Gastroenterol; 1995 Mar; 90(3):423-30. PubMed ID: 7872282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized placebo-controlled trial of pantoprazole for daytime sleepiness in GERD and obstructive sleep disordered breathing.
    Suurna MV; Welge J; Surdulescu V; Kushner J; Steward DL
    Otolaryngol Head Neck Surg; 2008 Aug; 139(2):286-90. PubMed ID: 18656731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD.
    Winter H; Kum-Nji P; Mahomedy SH; Kierkus J; Hinz M; Li H; Maguire MK; Comer GM
    J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):609-18. PubMed ID: 20400912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
    Bochenek WJ; Mack ME; Fraga PD; Metz DC
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1105-14. PubMed ID: 15569113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.
    Scholten T; Teutsch I; Bohuschke M; Gatz G
    Clin Drug Investig; 2007; 27(4):287-96. PubMed ID: 17358101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
    Fass R; Johnson DA; Orr WC; Han C; Mody R; Stern KN; Pilmer BL; Perez MC
    Am J Gastroenterol; 2011 Mar; 106(3):421-31. PubMed ID: 21224838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
    Glatzel D; Abdel-Qader M; Gatz G; Pfaffenberger B
    Digestion; 2007; 75 Suppl 1():69-78. PubMed ID: 17489035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.